Glutathione vs NMN: What the Research Compares

Glutathione and nicotinamide mononucleotide (NMN) are often placed side by side because both are discussed in the context of oxidative stress and ageing biology. Chemically and mechanistically they are not the same kind of molecule, and the published literature does not contain a head-to-head human trial comparing them. This page sets out what each compound is, what researchers measured for each, how regulators classify them, and where the two evidence bases touch.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here describes dosing, administration or personal use, and regulatory notes below are general information, not legal advice.

At a Glance: Two Different Molecular Classes

What Each Compound Is

Glutathione

Glutathione is a small tripeptide built from glutamate, cysteine and glycine. Its reactive thiol group is what gives it a role in redox chemistry: it serves as the electron donor for glutathione peroxidase enzymes. One of those enzymes, GPX4, is the specific checkpoint that restrains lipid peroxidation and ferroptotic cell death, and it appears repeatedly as an endpoint in recent oxidative-stress research (PMID 39216693). Once oxidised, glutathione has to be reduced again, and that regeneration step runs on NADPH — a dependency examined directly in a 2025 study of NAD kinase, which reported that NADPH homeostasis governed ferroptosis susceptibility (PMID 41462596).

NMN

NMN is a nucleotide intermediate in the NAD+ salvage pathway. It is not an antioxidant peptide; its described biology is about supplying NAD+, which then feeds enzymes such as sirtuins. A 2016 cell study on NAMPT, the enzyme that produces NMN inside cells, reported protection against 6-hydroxydopamine-induced neurotoxicity in PC12 cells through modulation of SIRT1 activity (PMID 27035562). A 2025 mouse study of alcohol-induced liver injury reported that β-NMN acted through activation of NAD+/SIRT1 signalling pathways (PMID 40819082).

Is There a Direct Comparison?

No. Across the papers verified for this page, no trial randomised participants or animals to glutathione versus NMN, and no study measured the two against a shared primary endpoint. The closest design is a 2023 report that examined the acute effect of different NAD+ precursors included in combined metabolic activators (PMID 37271226) — but that work compared NAD+ precursors with one another inside a multi-ingredient formulation, not NMN against glutathione as standalone interventions. Any claim that one of these molecules outperformed the other would not be traceable to a published comparison.

Because of that gap, the honest comparison is structural: the two literatures are read side by side, and the reader is left to see what each one actually measured.

Where the Two Literatures Intersect

The most interesting overlap is not pharmacological but biochemical. Several NMN studies used glutathione-dependent enzymes as their readout, which means NMN research has sometimes been reported through endpoints that belong to glutathione biology. A 2024 study reported that NMN mitigated neuroinflammation by enhancing GPX4-mediated ferroptosis defence in microglia (PMID 39216693), and a 2025 study reported that NMN mitigated hyperoxia-aggravated septic lung injury via the GPx4-mediated anti-ferroptosis signalling pathway in alveolar epithelial cells (PMID 40246251). GPX4 is the enzyme that consumes reduced glutathione, so these NMN experiments were measured at a glutathione-dependent step.

A complementary angle comes from the cofactor side: researchers reported in 2025 that NAD kinase governed ferroptosis susceptibility by orchestrating NADPH homeostasis (PMID 41462596). NAD kinase converts NAD+ into NADP+, and NADPH is what restores oxidised glutathione. That makes the NAD+ pool and the glutathione pool biochemically linked rather than interchangeable — a point reinforced by biochemistry work on engineered cycling of redox cofactors (PMID 36028482).

What Published NMN Studies Measured

• Neuroinflammation. The study in microglia reported enhanced GPX4-mediated ferroptosis defence with NMN (PMID 39216693).
• Lung injury. Researchers reported that NMN acted on the GPx4 anti-ferroptosis pathway in alveolar epithelial cells in a hyperoxia-aggravated septic lung injury model (PMID 40246251).
• Liver injury. A mouse model of alcohol-induced liver injury reported activation of NAD+/SIRT1 signalling with β-NMN (PMID 40819082).
• Cell preservation in vitro. A 2024 animal-science study reported that β-NMN improved chilled ram sperm quality in vitro by reducing oxidative stress damage (PMID 38575134).
• Precursor comparisons. The 2023 report assessed acute effects of different NAD+ precursors within combined metabolic activators (PMID 37271226).

Taken together, this NMN evidence base is dominated by animal models and cell systems rather than large human outcome trials, and several of its most-cited mechanisms were reported as ferroptosis and SIRT1 readouts (PMID 39216693) (PMID 40819082).

What Glutathione-Side Research in This Set Measured

Within the verified papers, glutathione appears mainly as a system rather than as an administered compound. The NAD kinase study framed glutathione regeneration as an NADPH-limited process and reported that this limitation shaped ferroptosis susceptibility (PMID 41462596). GPX4, the enzyme that uses glutathione, was the measured target in two separate NMN studies (PMID 39216693) (PMID 40246251). A 2022 review described how endogenous metabolites regulate mitophagy, placing redox-active small molecules inside broader quality-control signalling (PMID 34583624). Readers looking for oral or intravenous glutathione outcome trials will not find them in this citation set, and this page does not assert findings it cannot link.

Regulatory Status

The two molecules are treated differently by regulators. The US Food and Drug Administration has stated that NMN is excluded from the dietary supplement definition because it was authorised for investigation as a new drug, which is why NMN products have faced marketing challenges in the United States; NMN is not an approved drug for any indication. Glutathione is not an FDA-approved drug for systemic antioxidant, skin-lightening or anti-ageing use either; oral glutathione is marketed as a supplement ingredient in some jurisdictions, while injectable and inhaled forms generally appear through compounding, which carries its own restrictions. Material labelled "research use only" is not authorised for human administration. Rules differ by country and change over time, and this summary is general information rather than legal advice.

Adverse Events: What Studies Report

The verified papers on this page were designed around mechanism and efficacy endpoints rather than systematic safety surveillance. The NMN work was reported in rodent models and cell systems — microglia (PMID 39216693), alveolar epithelial cells (PMID 40246251), mouse liver (PMID 40819082) and in vitro sperm preservation (PMID 38575134) — and animal or cell findings do not establish a human tolerability profile. The acute NAD+ precursor study was the only design in this set positioned to describe short-term human exposure to precursors in a formulation context (PMID 37271226). No adverse-event comparison between glutathione and NMN exists in this literature, because no study administered both.

How Researchers Frame the Ageing Context

Both molecules are discussed inside longevity biology, which is a crowded and fast-moving field. A 2026 paper reported that an investigational compound, SRN-901, extended lifespan and healthspan in its model by targeting multiple ageing pathways (PMID 42011226), illustrating that multi-pathway framing is common in this area. Separately, a 2026 study described modulation of hepatic hypoxanthine metabolism relieving metabolic stress-related neurovascular disturbance through a liver–brain axis (PMID 42456994), a reminder that redox and metabolic endpoints are frequently entangled across organ systems. Neither paper compared glutathione with NMN.

Key Takeaways from the Comparison

1. They are different classes: a tripeptide versus a nucleotide NAD+ precursor.
2. No head-to-head study exists in the verified literature; any ranking between them is an extrapolation, not a reported result.
3. Their mechanisms are linked through NADPH and GPX4, which is why NMN studies have reported glutathione-dependent endpoints (PMID 41462596) (PMID 40246251).
4. Most NMN evidence summarised here came from animal and cell models (PMID 39216693).
5. Regulatory classification differs between the two and differs by jurisdiction.

Related reading: Glutathione overview and NMN overview.

References

• The multifaceted regulation of mitophagy by endogenous metabolites (Autophagy, 2022)
• The acute effect of different NAD(+) precursors included in the combined metabolic activators (Free Radical Biology & Medicine, 2023)
• SRN-901, a Novel Longevity Drug, Extends Lifespan and Healthspan by Targeting Multiple Aging Pathways (Drug Design, Development and Therapy, 2026)
• NADK Governs Ferroptosis Susceptibility by Orchestrating NADPH Homeostasis (Antioxidants, 2025)
• Nicotinamide mononucleotide mitigates neuroinflammation by enhancing GPX4-mediated ferroptosis defense in microglia (Brain Research, 2024)
• β-Nicotinamide mononucleotide alleviates alcohol-induced liver injury in a mouse model through activation of NAD(+)/SIRT1 signaling pathways (Hereditas, 2025)
• Nicotinamide mononucleotide mitigates hyperoxia-aggravated septic lung injury via the GPx4-mediated anti-ferroptosis signaling pathway in alveolar epithelial cells (Free Radical Biology & Medicine, 2025)
• Modulating hepatic hypoxanthine metabolism relieve metabolic stress-related neurovascular resilience disturbance via the liver-brain axis (Free Radical Biology & Medicine, 2026)
• β-Nicotinamide mononucleotide improves chilled ram sperm quality in vitro by reducing oxidative stress damage (Animal Bioscience, 2024)
• Directed evolution of phosphite dehydrogenase to cycle noncanonical redox cofactors via universal growth selection platform (Nature Communications, 2022)
• NAMPT protects against 6-hydroxydopamine-induced neurotoxicity in PC12 cells through modulating SIRT1 activity (Molecular Medicine Reports, 2016)